Short-course therapy for recurrent genital herpes and herpes labialis

Journal of Family Practice

Volumn 56, Issue 1, 2007, Pages 30-36

  Spruance, Spotswood ^a   Aoki, Fred Y ^b   Tyring, Stephen ^c   Stanberry, Lawrence ^d   Whitley, Richard ^e   Hamed, Kamal ^f  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF TEXAS   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

^e University of Alabama at Birmingham   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; FAMCICLOVIR; VALACICLOVIR;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COST OF ILLNESS; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG MEGADOSE; GENITAL HERPES; HEADACHE; HERPES LABIALIS; HUMAN; IMMUNOCOMPETENCE; NAUSEA; PATIENT COMPLIANCE; RECURRENT INFECTION; SHORT COURSE THERAPY; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACYCLOVIR; ANTIVIRAL AGENTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EARLY DIAGNOSIS; EVIDENCE-BASED MEDICINE; FAMILY PRACTICE; FEMALE; FOLLOW-UP STUDIES; HERPES GENITALIS; HERPES LABIALIS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; MALE; RECURRENCE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 33846444359     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Ho D. Time to hit HIV, early and hard. N Engl J Med 1995; 333:450-451.
2. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11-20.
3. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 2002; 34:958-962.
4. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin infect Dis 1998; 26:541-555.
5. Wald A, Ericsson M, Krantz E, Selkes S, Corey L. Oral shedding of herpes simplex virus type 2. Sex Transm Infect 2004; 80:272-276.
6. Mertz GJ, Rosenthal SL, Stanberry LR. Editorial response: Is herpes simplex virus type 1 (HSV-1) now more common than HSV-2 in first episodes of genital herpes? Sex Transm Dis 2003; 30:801-802.
7. Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex virus infection. N Engl J Med 1987; 316:1444-1449.
8. Smith JS, Robinson RJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 2002; 186(suppl 1): S3-S28.
9. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-1111.
10. Bierman SM. A retrospective study of 375 patients with genital herpes simplex infections seen between 1973 and 1980. Cutis 1983; 31:548-565.
11. Drob S, Loemer M, Lifshutz H. Genital herpes: the psychological consequences. Br J Med Psychol 1985;58:307-315.
12. Spruance SL, Kriesel JD. Treatment of herpes simplex labialis. Herpes 2002; 9:64-69.
13. Spruance SL, Overall JC Jr, Kern ER, Krueger GG, Pliam V, Miller W. The natural history of recurrent herpes simplex labialis. N Engl J Med 1977; 297:69-75.
14. Brown ZA, Kern ER, Spruance SL, Overall JC Jr. Clinical and virologic course of herpes simplex genitalis. West J Med 1979; 130:414-421.
15. Krueger GG, Spruance SL, Overall JC Jr. Herpes simplex labialis: a review of pathogenesis and therapy. J Clin Epidemiol Derm 1978; 1:19-37.
16. Spruance SL, Wenerstrom G. Pathogenesis of herpes simplex labialis: IV. Maturation of lesions during within 8 hours after onset and implications for antiviral treatment. Oral Surg Oral Med Oral Path 1984; 58:667-671.
17. Spruance SL. The natural history of recurrent oral-facial herpes simplex virus infection. Sem Dermatol 1992; 11:200-206.
18. Spruance SL. Herpes simplex labialis. In: Clinical Management of Herpes Viruses, Sacks SL, Straus SE, Whitley RJ, Griffiths PD, eds. Amsterdam, Netherlands; IOS Press; 1995.
19. Spruance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob Agents Chemother 2002; 46:2238-2243.
20. Spruance SL, Rea TL, Thoming C, Tucker R, Saltzman R, Boon R. Penciclovir cream for the treatment of herpes simplex labialis. JAMA 1997; 277:1374-1379.
21. Raborn GW, Martel AY, Lassonde M, et al; Worldwide Topical Penciclovir Collaborative Study Group. Effective treatment of herpes simplex labialis with penciclovir cream: combined results of two trials. J Am Dent Assoc 2002; 133:303-309.
22. Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir: a controlled trial. JAMA 1984; 251:2103-2107.
23. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD. Canadian Famciclovir Study Group. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. JAMA 1996; 276:44-49.
24. Tyring SK, Douglas JM Jr, Corey L, Spruance SL, Esmann J. The Valaciclovir International Study Group. A randomized, placebo-controlled comparison of oral valcyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch Dermatol 1998; 134:185-191.
25. Spruance S, Stewart JCB, Rowe NH, McKeough MB, Wenerstrom G, Freeman DJ. Treatment of herpes simplex labialis with oral acyclovir. J Infect Dis 1990; 161:185-190.
26. Spruance SL, Tyring SK, DeGregorio B, Miller C, Beutner K; Valaciclovir HSV Study Group. A largescale, placebo-controlled, dose-ranging trial of peroral Valaciclovir for episodic treatment of recurrent herpes genitalis. Arch Intern Med 1996; 156:1729-1735.
27. Spruance SL, Jones TM, Blatter MM, et al. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother 2003; 47:1072-1080.
28. Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002; 34:944-948.
29. Aoki FY, Tyring S, Dias-Mitoma F, Gross G, Gao J, Hamed K. Single-day patient initiated famciclovir therapy for recurrent genital herpes: a randomized double-blind, placebo-controlled trial. Clin Infect Dis 2006; 42:8-13.
30. Spruance S, Bodsworth N, Resnick H, et al. Single-dose, patient-initiated famciclovir; a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol 2006; 55:47-53.
31. Reichman RC, Badger GJ, Guinan ME, et al. Topically administered acyclovir in the treatment of recurrent herpes simplex genitalis: a controlled trial. J Infect Dis 1983; 147:336-340.
32. Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir. Clin Pharmacokinet 1996; 31:1-8.
33. Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, Perkins RM, Vere Hodge RA. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992; 36:2747-2757.
34. Vere Hodge RA, Perkins RM. Mode of action of 9-(4-hydroxy-3- hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother 1989; 33:223-229.
35. Spruance SL, Freeman DJ. Topical treatment of cutaneous herpes simplex virus infections. Antivir Res 1990; 14:305-321.